Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) EBITDA (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed EBITDA for 3 consecutive years, with -$20.8 million as the latest value for Q4 2025.

  • For Q4 2025, EBITDA fell 25.32% year-over-year to -$20.8 million; the TTM value through Dec 2025 reached -$83.6 million, down 27.08%, while the annual FY2025 figure was -$83.6 million, 27.08% down from the prior year.
  • EBITDA hit -$20.8 million in Q4 2025 for Artiva Biotherapeutics, up from -$21.4 million in the prior quarter.
  • Across five years, EBITDA topped out at $11.4 million in Q3 2023 and bottomed at -$21.4 million in Q3 2025.
  • Average EBITDA over 3 years is -$14.6 million, with a median of -$17.3 million recorded in 2024.
  • Year-over-year, EBITDA tumbled 251.05% in 2024 and then fell 18.53% in 2025.
  • Artiva Biotherapeutics' EBITDA stood at -$12.0 million in 2023, then crashed by 38.47% to -$16.6 million in 2024, then dropped by 25.32% to -$20.8 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$20.8 million, -$21.4 million, and -$21.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.